Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
28 results
D1.50 - Allergic Bronchopulmonary Aspergillosis in a Tertiary Allergy Center: Clinical Characteristics, Radiologic Subtypes, and Biologic Use
D1.54 - Latex-Induced Occupational Asthma: An Underrecognized Hazard in the Electronics and Cable Industry
D1.46 - Molecular patterns of fungal sensitization in patients with asthma and allergic rhinitis: evidence from real-life clinical practice
D1.47 - Assessment of Asthma Control in Elderly Patients Using Forced Oscillation Technique, Spirometry, and Asthma Control Test in Relation to GINA Classification
D1.48 - Early-Onset Multiorgan Allergic Phenotype with Transformation into Controlled Asthma in a 2-Year-Old Child: The Role of Molecular Diagnostics (ALEX²) in Risk Stratification
D1.49 - Component-Resolved Pet Allergen Sensitization Identifies Adolescents With Airway Inflammation and Bronchial Hyperresponsiveness
D1.51 - Evaluation of the Correlation Between Skin Prick Test, Specific Immunoglobulin E Levels and Clinical Findings in Children with Cat Allergen Sensitization
D1.52 - The Borg Fallacy in Olympic Athletes: Symptom Perception Fails to Identify Airway Hyperresponsiveness
D1.55 - Monosensitization to Der p 23 in house dust mite allergy in daily clinical practice in a county of Gipuzkoa, Basque Country, Spain: a retrospective and descriptive analysis
D1.57 - New allergens registered in the WHO/IUIS Allergen Database in 2025: new and old foes
D1.58 - “Evaluation of Chronic Cough in Patients with Allergic Disease, GERD, and Chronic Rhinosinusitis”
D1.60 - Clinical Characteristics of Children with Patch Test–Positive Allergic Contact Dermatitis: Effects of Treatment on Quality of Life
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download